Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Oesophagogastric Cancer × Bevacizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 10 Colonic Neoplasms 4 Carcinoma, Hepatocellular 4 Carcinoma, Non-Small-Cell Lung 3 Rectal Neoplasms 2 Ovarian Neoplasms 2 Fallopian Tube Neoplasms 2 Astrocytoma 2 Vipoma 1 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Spinal Cord Neoplasms 1 Somatostatinoma 1 Small Cell Lung Carcinoma 1 Recurrence 1 Progression Free Survival 1 Oropharyngeal Neoplasms 1 Oesophagogastric Cancer 1 Neuroendocrine Tumors 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Mouth Neoplasms 1 Lymphoid Interstitial Pneumonia 1 Lung Neoplasms 1 Laryngeal Neoplasms 1 Insulinoma 1 Inflammatory Breast Neoplasms 1 Hypopharyngeal Neoplasms 1 Glucagonoma 1

Interventions

Neoadjuvant Therapy 1 Lapatinib 1 Epirubicin 1 Cisplatin 1 Chemotherapy, Adjuvant 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00450203 2016-12-01

ST03

Medical Research Council

Phase 2/3 Unknown

Gastrointestinal

Oesophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡